SCYNEXIS Reports Positive Phase 1 Results for IV Antifungal SCY-247; Shares Rise 2%

SCYNEXIS (SCYX) reported positive Phase 1 results for intravenous SCY-247, an antifungal candidate for invasive fungal infections. The drug was generally well tolerated in 56 healthy participants, with no drug-related serious adverse events, and doses of 50 mg or higher achieved target drug exposure. The company plans to initiate Phase 2 development in 2027, subject to regulatory agreement, backed by up to $214 million in potential BARDA funding. The stock was trading up 2.04% at $3.86.